文献速递心脑血管急症复苏、休克与脓毒症重症综合管理与镇静镇痛

格列本脲对大鼠心脏骤停后体感诱发电位的影响

The effect of Glibenclamide on somatosensory evoked potentials after cardiac arrest in rats.
PubMed 文献 · Neurocrit Care · 2021-10-01
一句话结论大鼠心脏骤停模型中,格列本脲改善昏迷恢复、觉醒和脑干功能,并促进体感诱发电位N10波幅恢复至基线。

研究在大鼠8分钟窒息性心脏骤停模型中进行,16只雄性Wistar大鼠随机分为格列本脲组(n=8)和对照组(n=8)。格列本脲在自主循环恢复后10分钟腹腔注射负荷量10 μg/kg,随后1.6 μg/kg每8小时一次维持24小时。结果显示格列本脲组神经功能缺损评分亚项更高(P=0.007),SSEP N10波幅在30、60、90、120分钟各时间点均显著优于对照组,120分钟恢复至基线;组织学显示对照组缺血神经元损伤比例显著更高(P=0.004)。作者认为该药值得进一步探索作为改善心脏骤停后功能预后的潜在药物。

要点

  • 大鼠8分钟窒息性心脏骤停模型中,格列本脲组神经功能缺损评分亚项(觉醒和脑干功能)高于对照组(P=0.007)。
  • 格列本脲组SSEP N10波幅在心脏骤停后30、60、90分钟(P<0.001)和120分钟(P=0.003)均显著优于对照组。
  • 格列本脲组N10波幅在心脏骤停后120分钟恢复至基线值,提示早期电生理恢复。
  • 对照组Cresyl violet染色显示缺血神经元损伤百分比显著高于格列本脲组(P=0.004)。
  • 作者认为格列本脲值得进一步探索作为改善心脏骤停后功能预后的潜在药物。

适用人群与场景

  • 雄性Wistar大鼠,8分钟窒息性心脏骤停模型,共16只,格列本脲组8只、对照组8只。

处置流程与药物剂量

  • 格列本脲负荷量10 μg/kg腹腔注射,于自主循环恢复后10分钟给予;维持量1.6 μg/kg每8小时一次,持续24小时。

研究设计与关键结果

  • 研究类型:大鼠心脏骤停模型实验;样本量16只雄性Wistar大鼠,格列本脲组8只、对照组8只。
  • 格列本脲组神经功能缺损评分亚项(觉醒和脑干功能)高于对照组(P=0.007)。
  • SSEP N10波幅:格列本脲组在30、60、90分钟(P<0.001)和120分钟(P=0.003)均显著优于对照组;格列本脲组N10波幅在120分钟恢复至基线。
  • Cresyl violet染色:对照组缺血神经元损伤百分比显著高于格列本脲组(P=0.004)。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠心脏骤停模型)。
  • 局限:作者结论指出该药物作为改善心脏骤停后功能预后的潜在疗法值得进一步探索(warrants further exploration)。

对床旁实践的改变

  • 作者认为格列本脲值得进一步探索作为改善心脏骤停后功能预后的潜在药物。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Science continues to search for a neuroprotective drug therapy to improve outcomes after cardiac arrest (CA). The use of glibenclamide (GBC) has shown promise in preclinical studies, but its effects on neuroprognostication tools are not well understood. We aimed to investigate the effect of GBC on somatosensory evoked potential (SSEP) waveform recovery post CA and how this relates to the early prediction of functional outcome, with close attention to arousal and somatosensory recovery, in a rodent model of CA.

METHODS: Sixteen male Wistar rats were subjected to 8-min asphyxia CA and assigned to GBC treatment (n = 8) or control (n = 8) groups. GBC was administered as a loading dose of 10 μg/kg intraperitoneally 10 min after the return of spontaneous circulation, followed by a maintenance dosage of 1.6 μg/kg every 8 h for 24 h. SSEPs were recorded from baseline until 150 min following CA. Coma recovery, arousal, and brainstem function, measured by subsets of the neurological deficit score (NDS), were compared between both groups. SSEP N10 amplitudes were compared between the two groups at 30, 60, 90, and 120 min post CA.

RESULTS: Rats treated with GBC had higher sub-NDS scores post CA, with improved arousal and brainstem function recovery (P = 0.007). Both groups showed a gradual improvement of SSEP N10 amplitude over time, from 30 to 120 min post CA. Rats treated with GBC showed significantly better SSEP recovery at every time point (P < 0.001 for 30, 60, and 90 min; P = 0.003 for 120 min). In the GBC group, the N10 amplitude recovered to baseline by 120 min post CA. Quantified Cresyl violet staining revealed a significantly greater percentage of damage in the control group compared with the GBC treatment group (P = 0.004).

CONCLUSIONS: Glibenclamide improves coma recovery, arousal, and brainstem function after CA with decreased number of ischemic neurons in a rat model. GBC improves SSEP recovery post CA, with N10 amplitude reaching the baseline value by 120 min, suggesting early electrophysiologic recovery with this treatment. This medication warrants further exploration as a potential drug therapy to improve functional outcomes in patients after CA.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Lachance BB, Wang Z, Badjatia N, et al. The effect of Glibenclamide on somatosensory evoked potentials after cardiac arrest in rats. Neurocrit Care. 2021. PMID: 34599418. doi:10.1007/s12028-021-01350-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。